||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (January 2017) (Learn how and when to remove this template message)|
||This article may require copy editing for grammar, style, cohesion, tone, or spelling. (January 2017) (Learn how and when to remove this template message)|
|Trade names||Atelec (アテレック), Cilacar|
|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||492.52 g/mol|
|3D model (Jmol)|
Cilnidipine (INN) is a calcium channel blocker, it is the novel calcium antagonist accompanied with L-type and N-type calcium channel blocking functions. It was jointly developed by Fuji Viscera Pharmaceutical Company and Ajinomoto, which are based in Japan, and was approved to come into market for the first time and used as anti-hypertensive in 1995. Unlike other calcium antagonists, Cilnidipine can act on the N-type calcium channel in addition to acting on L-type calcium channel like most other calcium antagonists. Cilnidipine is approved for use in Japan, China, India, Korea, and some European countries. Hypertension is the most common cardiovascular disease. Around 50 million individuals in the United States and 1 billion individuals worldwide are affected by hypertension
Cilnidipine is used to manage hypertension. Due to its blocking action at N-type and L type calcium channel, cilnidipine dilates both arterioles and venules, reducing the pressure in the capillary bed.
Cilnidipine has enhanced lipophilicity, leading to prolonged anti-hypertensive effects, correlated with occupancy of the binding site. In 24-hour clinical assessment, once-daily administration of cilnidipine reduced blood pressure (citation needed). The inhibitory effect on the N-type Ca2+ channel may bestow an additional clinical advantage for the treatment of hypertension, such as suppression of reflex tachycardia (citation needed).
In Bangladesh it is marketed by The Acme Laboratories Ltd. under the brand name Duocard, available as both 5 mg & 10 mg and Opsonin Pharma Ltd. In India it is marketed by JBCPL under the brand name "Cilacar" and is available in 5 mg, 10 mg, 20 mg and other combinations. In Japan it is marketed by Ajinomoto Pharmaceuticals Co., Ltd.under the brand name "Atelec". In the United States it is available through different brands, including "Atelec" and "Cilacar."
- Löhn M, Muzzulini U, Essin K, et al. (May 2002). "Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C". J. Hypertens. 20 (5): 885–93. doi:10.1097/00004872-200205000-00023. PMID 12011649.
- 1. Cardiovascular Therapeutics 27 (2009) 2. Cardiovascular Drugs and Therapy 1997 3. Can J Anesth. 2002. 4. Clinical and Experimental Hypertension,2009. 5. J Clin Hypertens (Greenwich). 2013 6. Hypertens Res 2003; 7. Journal of Diabetes Investigation; 2012.8 .Journal of Cardiology (2009) . 9 J Cardiovasc Pharmacol; 2007 10.J Cardiovasc Pharmacol 2004, 11 Antihypertensive Drug 2012, 12 J Hypertens. 2010 May. 13 J Hypertens. 2010 14 Hypertens Res. 2012 15 Diabetes Res Clin Pract. 2012 16 Neurochem Int. 2012, 17 J. Neurochem. (2009) 18 Geriatr Gerontol Int 2008; , 19 Biol. Pharm. Bull. (2004), 20 Clin Calcium. 2010 20. http://buymedicinesx.com/buycilacarpricesideeffects2/